These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2958850)

  • 1. Decapeptyl in the treatment of metastatic prostatic cancer. Comparative study with pulpectomy.
    Botto H; Richard F; Mathieu F; Camey M
    Prog Clin Biol Res; 1987; 243A():199-206. PubMed ID: 2958850
    [No Abstract]   [Full Text] [Related]  

  • 2. Decapeptyl in the treatment of advanced prostatic cancer: comparative study with pulpectomy.
    Botto H; Richard F; Mathieu F; Camey M
    Prog Clin Biol Res; 1989; 303():53-60. PubMed ID: 2528740
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
    Fretin J; Demerle F; Jardin A
    Prog Clin Biol Res; 1987; 243A():245-7. PubMed ID: 2958855
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy.
    De Sy WA; De Wilde P; De Meyer JM; Casselman J; Desmet R; Renders G; Schelfhout W
    Acta Urol Belg; 1988; 56(4):581-8. PubMed ID: 2974680
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of newly diagnosed metastatic carcinoma of the prostate.
    Elder JS; Catalona WJ
    Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

  • 12. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 13. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 14. [New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S
    Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of prostatic cancer].
    J Urol (Paris); 1984; 90(10):619-48. PubMed ID: 6242517
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
    Givner ML; Millard OH
    Prog Clin Biol Res; 1987; 243A():439-43. PubMed ID: 2958865
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.